[HTML][HTML] Intermethod comparability analyses of gepotidacin antimicrobial susceptibility tests using a large collection of globally collected Escherichia coli and …
SJR Arends, D Butler, N Scangarella-Oman… - … and Infectious Disease, 2024 - Elsevier
Gepotidacin (GSK2140944) is a novel, bactericidal, first in class triazaacenaphthylene
bacterial type II topoisomerase inhibitor in development for the treatment of uncomplicated …
bacterial type II topoisomerase inhibitor in development for the treatment of uncomplicated …
Intermethod comparability analyses of gepotidacin antimicrobial susceptibility tests using a large collection of globally collected Escherichia coli and Staphylococcus …
SJR Arends, D Butler, N Scangarella-Oman… - Diagnostic …, 2024 - europepmc.org
Gepotidacin (GSK2140944) is a novel, bactericidal, first in class triazaacenaphthylene
bacterial type II topoisomerase inhibitor in development for the treatment of uncomplicated …
bacterial type II topoisomerase inhibitor in development for the treatment of uncomplicated …
Intermethod comparability analyses of gepotidacin antimicrobial susceptibility tests using a large collection of globally collected Escherichia coli and Staphylococcus …
SJR Arends, D Butler… - Diagnostic … - pubmed.ncbi.nlm.nih.gov
Gepotidacin (GSK2140944) is a novel, bactericidal, first in class triazaacenaphthylene
bacterial type II topoisomerase inhibitor in development for the treatment of uncomplicated …
bacterial type II topoisomerase inhibitor in development for the treatment of uncomplicated …